JP2015502915A - ＣＤ１ｄに対する抗体 - Google Patents

ＣＤ１ｄに対する抗体 Download PDF

Info

Publication number
JP2015502915A
JP2015502915A JP2014534890A JP2014534890A JP2015502915A JP 2015502915 A JP2015502915 A JP 2015502915A JP 2014534890 A JP2014534890 A JP 2014534890A JP 2014534890 A JP2014534890 A JP 2014534890A JP 2015502915 A JP2015502915 A JP 2015502915A
Authority
JP
Japan
Prior art keywords
seq
cd1d
antigen
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014534890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502915A5 (https=
Inventor
ジョナサン・カンナン・ナンビアー
リン・ドロシー・ポールトン
アダム・クラーク
アンドリュー・ジェームズ・パウ
デブラ・タンヴァキス
ジョージ・コプシダス
アンソニー・ゲラルド・ドイル
マシュー・ポラード
フセイン・ムスタファ
Original Assignee
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904190A external-priority patent/AU2011904190A0/en
Application filed by テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド filed Critical テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド
Publication of JP2015502915A publication Critical patent/JP2015502915A/ja
Publication of JP2015502915A5 publication Critical patent/JP2015502915A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014534890A 2011-10-14 2012-10-15 ＣＤ１ｄに対する抗体 Pending JP2015502915A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161547307P 2011-10-14 2011-10-14
AU2011904190A AU2011904190A0 (en) 2011-10-14 Antibodies to CD1d
US61/547,307 2011-10-14
AU2011904190 2011-10-14
PCT/AU2012/001247 WO2013053021A1 (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d

Publications (2)

Publication Number Publication Date
JP2015502915A true JP2015502915A (ja) 2015-01-29
JP2015502915A5 JP2015502915A5 (https=) 2015-12-03

Family

ID=48081279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534890A Pending JP2015502915A (ja) 2011-10-14 2012-10-15 ＣＤ１ｄに対する抗体

Country Status (14)

Country Link
US (1) US20140286957A1 (https=)
EP (1) EP2766042A4 (https=)
JP (1) JP2015502915A (https=)
KR (1) KR20140108520A (https=)
CN (1) CN104144700B (https=)
AU (1) AU2012323781B8 (https=)
BR (1) BR112014008691A2 (https=)
CA (1) CA2850961A1 (https=)
EA (1) EA201400447A1 (https=)
IL (1) IL231975A0 (https=)
MX (1) MX2014004326A (https=)
SG (1) SG11201400521PA (https=)
WO (1) WO2013053021A1 (https=)
ZA (1) ZA201401776B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511062A (ja) * 2018-12-07 2022-01-28 ライフアーク ヒト化抗ｉｌ１７ｂｒ抗体
JP2023538379A (ja) * 2020-08-18 2023-09-07 セファロン エルエルシー 抗ｐａｒ－２抗体及びそれらの使用方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) * 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
SMT202100564T1 (it) * 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
CA3020555A1 (en) * 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
PL3440105T3 (pl) * 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
EP4263612A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Mesothelin binding molecules and uses thereof
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
CN116217704B (zh) * 2022-10-25 2025-08-15 南京医科大学 一种抑制肝细胞凋亡的表面分子及其应用
CN120548186A (zh) * 2022-12-21 2025-08-26 得克萨斯大学体系董事会 功能增强的表达cd3和itcr的工程化的自然杀伤细胞用于过继免疫疗法
WO2024226794A1 (en) * 2023-04-26 2024-10-31 The Trustees Of Indiana University Composition and methods for treatment of spinal cord injury and traumatic brain injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092615A2 (en) * 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002923A1 (en) * 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20100035843A1 (en) * 2007-02-12 2010-02-11 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092615A2 (en) * 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.MASS.SPECTROM.SOC.JPN, vol. 45, no. 3, JPN6016046412, 1997, pages 355 - 366 *
ドージンニュース, vol. no.109, JPN6016046410, 2004, pages 1 - 7 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511062A (ja) * 2018-12-07 2022-01-28 ライフアーク ヒト化抗ｉｌ１７ｂｒ抗体
JP2023538379A (ja) * 2020-08-18 2023-09-07 セファロン エルエルシー 抗ｐａｒ－２抗体及びそれらの使用方法
JP7848185B2 (ja) 2020-08-18 2026-04-20 セファロン エルエルシー 抗ｐａｒ－２抗体及びそれらの使用方法

Also Published As

Publication number Publication date
CA2850961A1 (en) 2013-04-18
SG11201400521PA (en) 2014-08-28
EP2766042A4 (en) 2015-05-27
CN104144700B (zh) 2016-10-19
BR112014008691A2 (pt) 2017-06-13
ZA201401776B (en) 2016-01-27
AU2012323781A8 (en) 2015-05-14
KR20140108520A (ko) 2014-09-11
AU2012323781B2 (en) 2015-04-23
NZ622050A (en) 2016-07-29
AU2012323781B8 (en) 2015-05-14
EA201400447A1 (ru) 2014-09-30
WO2013053021A1 (en) 2013-04-18
IL231975A0 (en) 2014-05-28
MX2014004326A (es) 2014-09-25
EP2766042A1 (en) 2014-08-20
US20140286957A1 (en) 2014-09-25
CN104144700A (zh) 2014-11-12
AU2012323781A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
US11746153B2 (en) Binding molecules specific for FcγRIIA and uses thereof
JP2015502915A (ja) ＣＤ１ｄに対する抗体
JP6548696B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
CN106794129B (zh) 对il-21具有特异性的结合分子及其用途
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP7610515B2 (ja) ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体
KR101767717B1 (ko) 항-인간 xcr1 항체
JP6501650B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
TW202229337A (zh) 犬抗體變異體
US20230227559A1 (en) New antibody blocking human fcgriiia and fcgriiib
WO2025228315A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
WO2019191668A1 (en) Binding molecules specific for fcyriia and uses thereof
CA3022479C (en) Binding molecules specific for fc.gamma.riia and uses thereof
NZ622050B2 (en) ANTIBODIES TO CD1d

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170731